# Viking Therapeutics to Participate at Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-239640de
Ticker: VKTX
Company: Viking Therapeutics
Source: Viking Therapeutics
Published: 2026-05-21 11:05 EST
Original Source URL: https://ir.vikingtherapeutics.com/2026-05-21-Viking-Therapeutics-to-Participate-at-Upcoming-Investor-Conferences
## Summary

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...

## Article Body
Viking Therapeutics to Participate at Upcoming Investor Conferences

, / PRNewswire / -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference in June.

Details of the company's participation are as follows:

William Blair 46th Annual Growth Stock Conference Details: Viking management will deliver a corporate presentation, followed by a breakout session, and participate in investor meetings. Conference Dates: June 2-4, 2026 Presentation Date/Time: Tuesday, June 2 nd at 2:00 pm – 2:30 pm CT Breakout session: Tuesday, June 2 nd at 2:40 pm – 3:10 pm CT Location: Chicago, IL

Jefferies Global Healthcare Conference Details: Viking management will participate in a fireside chat and investor meetings. Conference Dates: June 3-4, 2026 Fireside Chat Date/Time: Thursday, June 4 th at 1:25 pm – 1:55 pm ET Location: New York, NY Webcast available

A live webcast of the Jefferies fireside chat may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts . Additionally, a replay of the webcast will be available on the Viking website following the conference.

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 ( GLP-1 ) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com .

SOURCE Viking Therapeutics, Inc.

For further information: Contacts: Viking Therapeutics, Inc., Greg Zante, Chief Financial Officer, 858-704-4672, gzante@vikingtherapeutics.com; Vida Strategic Partners, Stephanie Diaz (Investors), 415-675-7401, sdiaz@vidasp.com; Jennifer Arcure (Media), 927-603-0681, jarcure@vidasp.com
## Recent Company News
- 2026-06-24 11:05 EST — [Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults](https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-initiation-of-phase-1-study-to-evaluate-novel-amyl-743d8a79) — Source: Viking Therapeutics
- 2026-06-11 11:05 EST — [Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer](https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-appointment-of-hubert-c-chen-m-d-as-chief-medical--ca51f016) — Source: Viking Therapeutics
- 2026-05-21 11:05 EST — [Viking Therapeutics to Participate at Upcoming Investor Conferences](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-239640de) — Source: Viking Therapeutics
- 2026-05-12 11:05 EST — [Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026) — Source: Viking Therapeutics
- 2026-05-05 11:05 EST — [Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-two-poster-presentations-at-european-congress-on-obesity-eco-2026) — Source: Viking Therapeutics
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)